<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01356732</url>
  </required_header>
  <id_info>
    <org_study_id>09 162 02</org_study_id>
    <nct_id>NCT01356732</nct_id>
  </id_info>
  <brief_title>Determination of the 90% Effective Dose of a Sufentanil Bolus in Analgesia During Lateral Decubitus of Mechanically Ventilated Patients</brief_title>
  <acronym>REANURSUF</acronym>
  <official_title>Determination of the 90% Effective Dose of a Sufentanil Bolus in Analgesia During Lateral Decubitus of Mechanically Ventilated Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mechanically ventilated patients experiencing pain are frequent in intensive care units (ICU)
      however their treatment remains unclear. This prospective pharmacodynamic study relates to
      the analgesia of procedural pains. The primary objective was to determine the 90% effective
      dose (ED) of a sufentanil bolus to obtain a satisfactory analgesia (defined by a Behavioral
      Pain Scale (BPS) at 3 or 4) during lateral decubitus (LD) of mechanically ventilated
      patients.

      Material and Method. Patients who, at rest before the 48th hour of mechanical ventilation,
      reach the objectives of BPS at 3 or 4 and Ramsay sedation score between 3 and 5, were
      included.

      During a 72h evaluation phase, BPS was used to measure the efficiency of a bolus of
      sufentanil on the analgesia of the LD. The dose of this bolus was raised gradually every new
      LD until BPS was at 3 or 4.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effective dose (ED) of a sufentanil bolus to obtain a satisfactory analgesia (defined by a Behavioral Pain Scale (BPS) at 3 or 4)</measure>
    <time_frame>five days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Sufentanil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sufentanil</intervention_name>
    <description>From 0 to 0,05 µg/kg to a maximum of 4 µg/kg of sufentanil. 7 minutes before nursing 3 nursing per day during 3 days</description>
    <arm_group_label>Sufentanil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  48th hour of mechanical ventilation

          -  mechanical invasive ventilation

          -  48th hour midazolam sedation

          -  Behavioral Pain Scale (BPS) at 3 or 4

          -  mechanical ventilation of 5 days duration

        Exclusion Criteria:

          -  Pregnant or breast-feeding woman

          -  Impossibility of evaluation of the BPS tetraplegia, curare-link , post anoxic coma
             encephalic death

          -  Indication of deep conscious-sedation, malignant cranial trauma, toxic shock, acute
             respiratory distress syndrome

          -  Extra renal clearance OU people in hemodialysis

          -  Severe renal failure (creatinine clearance &lt;15ml/min)

          -  Severe hepatic failure

          -  State of consciousness with impossibility to use self-assessment scale

          -  Body mass index &gt;35 ou &lt;18

          -  Sufentanil midazolam paracetamol allergy or contraindication

          -  Guardianship or confirmed criminal Subject who give his informed consent

          -  Morphinic other than sufentanil (morphine, alfentanil fentanyl, remifentanil,
             nalbuphine, codeine, buprenorphine)

          -  Antalgic other than sufentanil and paracetamol ( tramadol nefopam, ketamine,
             dextropropoxyphene, non steroidal anti-inflammatory drug )

          -  MAO inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Fourcade</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de réanimation - Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Chaveron D, Silva S, Sanchez-Verlaan P, Conil JM, Sommet A, Geeraerts T, Génestal M, Minville V, Fourcade O. The 90% effective dose of a sufentanil bolus for the management of painful positioning in intubated patients in the ICU. Eur J Anaesthesiol. 2012 Jun;29(6):280-5. doi: 10.1097/EJA.0b013e328352234d.</citation>
    <PMID>22388706</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2011</study_first_submitted>
  <study_first_submitted_qc>May 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2011</study_first_posted>
  <last_update_submitted>May 10, 2017</last_update_submitted>
  <last_update_submitted_qc>May 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mechanical ventilation</keyword>
  <keyword>Midazolam</keyword>
  <keyword>Ramsay</keyword>
  <keyword>Sufentanil</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sufentanil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

